Search

Your search keyword '"Macintyre, Elizabeth"' showing total 1,123 results

Search Constraints

Start Over You searched for: Author "Macintyre, Elizabeth" Remove constraint Author: "Macintyre, Elizabeth"
1,123 results on '"Macintyre, Elizabeth"'

Search Results

1. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

2. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

3. Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma

4. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

7. TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2

8. Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL

10. Multimodal cartography of human lymphopoiesis reveals B and T/NK/ILC lineages are subjected to differential regulation

11. Distinct subsets of multi-lymphoid progenitors support ontogeny-related changes in human lymphopoiesis

12. Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma

14. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

15. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

16. DNA methylation as a new tool for the differential diagnosis between T‐LBL and lymphocyte‐rich thymoma.

17. A vision to the future: value-based laboratory medicine.

19. Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients

20. Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders

22. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis

26. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group

27. Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

28. Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

29. Data from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

30. A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

31. Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins

32. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm

33. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL

34. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

35. Efficacy of Ruxolitinib Therapy in a Patient With Severe Enterocolitis Associated With a STAT3 Gain-of-Function Mutation

36. Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma

37. Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study

38. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

40. Loss of ARHGEF1 causes a human primary antibody deficiency

41. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

42. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study

43. S108: ATP CITRATE LYASE IS AN ESSENTIAL PLAYER OF THE METABOLIC REWIRING INDUCED BY PTEN LOSS DURING T-ALL DEVELOPMENT

44. P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN

45. P321: TNF-MEDIATED CELL DEATH: AN ACTIONABLE TARGET FOR IMMUNOTHERAPY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

46. PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0

47. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.

48. Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia

49. Supplementary Figures 1 - 3, Table 1 from Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia

Catalog

Books, media, physical & digital resources